Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline
Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline
复制标题
DOI：
10.1016/j.socscimed.2016.01.005
复制
发表时间：
2016-02-01
影响因子：
5.4
通讯作者：
Mossialos, Elias
中科院分区：
文献类型：
--
作者：
Brogan, David M.;Mossialos, Elias
在过去的十年中，人们越来越认识到抗生素耐药性细菌的增长和新型抗菌疗法的生产相对下降。这两种力量结合在一起，对发达国家和发展中国家的全球卫生构成潜在的严重威胁。目前的市场力量并没有提供适当的激励措施来刺激新抗生素的开发，因此我们提出了一个新的激励机制：抗生素期权市场。这一机制以金融看涨期权的原则为模型，允许付款人在开发的早期阶段购买权利，以便在抗生素获得市场批准时以折扣价购买抗生素。本文展示了这样一个模型的预期净现值的一个典型的抗菌项目的效果。作为应对即将到来的抗生素危机的综合战略的一部分，抗生素期权市场可以有效地刺激企业和公共投资抗生素研究和开发。(C)2016由Elsevier Ltd.出版
Over the past decade, there has been a growing recognition of the increasing growth of antibiotic resistant bacteria and a relative decline in the production of novel antibacterial therapies. The combination of these two forces poses a potentially grave threat to global health, in both developed and developing countries. Current market forces do not provide appropriate incentives to stimulate new antibiotic development, thus we propose a new incentive mechanism: the Options Market for Antibiotics. This mechanism, modelled on the principle of financial call options, allows payers to buy the right, in early stages of development, to purchase antibiotics at a discounted price if and when they ever make it to market approval. This paper demonstrates the effect of such a model on the expected Net Present Value of a typical antibacterial project. As part of an integrated strategy to confront the impending antibiotic crisis, the Options Market for Antibiotics may effectively stimulate corporate and public investment into antibiotic research and development. (C) 2016 Published by Elsevier Ltd.